FLT3

EHA 2019 | What effect does gilteritinib have on FLT3 mutated relapsed/refractory AML?

L:

At the 24th Congress of the European Hematology Association (EHA), Alexander Perl from the University of Pennsylvania, US, presented the data from the ADMIRAL phase III trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid leukemia (AML). Patients were randomized 2:1 to receive either gilteritinib or one of four standard salvage chemotherapy treatments. The favorable outcomes of gilteritinib observed in this trial (increased complete response rate and overall survival) led to its FDA approval for R/R AML.